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ABSTRACT
Invasive fungal infections (IFIs) have risen dramatically in recent years among high risk immunocompromised patients. 
Rapid detection of fungal pathogens is crucial to timely and accurate antifungal therapy. Two multiplex polymerase 
chain reaction (PCR) assays were developed to detect major fungal species that cause invasive infections and identify 
resistant species. Genus specific primers for Candida, Aspergillus, Fusarium and species specific primers for Candida 
glabrata, Candida krusei and Aspergillus terreus which are known to be clinically resistant species, were designed from 
the internal transcribed spacer (ITS) regions of ribosomal ribonucleic acid (rRNA) gene complex. Both assays were 
performed simultaneously to promote rapid detection of fungal isolates based on distinct amplicon sizes. Inclusion of the 
universal fungal primers ITS 1 and ITS 4 in the genus specific assay produced a second amplicon for each isolate which 
served to confirm the detection of a fungal target. The limit of detection for the genus specific assay was 1 nanogram 
(ng) deoxyribonucleic acid (DNA) for Aspergillus fumigatus and Candida albicans, 0.1 ng DNA for Fusarium solani, while 
the species-specific assay detected 0.1 ng DNA of A. terreus and 10 picogram (pg) DNA of C. krusei and C. glabrata. The 
multiplex PCR assays, apart from universal detection of any fungal target, are able to detect clinically important fungi 
and differentiate resistant species rapidly and accurately, which can contribute to timely implementation of effective 
antifungal regime. 
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ABSTRAK
Jangkitan kulat invasif telah meningkat sejak kebelakangan  ini dalam kalangan pesakit terimunokompromi. Pengesanan 
segera patogen kulat adalah amat perlu supaya terapi anti kulat yang bersesuaian dapat diberikan. Dua asai tindak 
balas rantai polimerase multipleks telah dibangunkan untuk mengesaan spesies utama patogen kulat yang menyebabkan 
infeksi invasif dan mengenal pasti spesies resistan. Primer khusus untuk genus Candida, Aspergillus, Fusarium dan 
khusus untuk spesies Candida glabrata, Candida krusei dan Aspergillus terreus yang merupakan spesies  rintang telah 
direka cipta berdasarkan jujukan mentranskripsi jarak dalaman (ITS) kompleks gen rRNA. Kedua-dua asai dijalankan 
serentak untuk mempercepatkan pengesanan pencilan kulat berdasarkan saiz amplikon yang terhasil. Dalam asai 
khusus untuk pengesanan genus, primer universal kulat disertakan bersama supaya amplikon kedua terhasil bagi setiap 
pencilan yang mengesahkan kehadiran kulat. Tahap pengesanan untuk asai khusus genus adalah 1 nanogram (ng) asid 
deoksiribonukleik (DNA) Aspergillus fumigatus dan Candida albicans serta 0.1 ng DNA Fusarium solani, manakala asai 
khusus spesies dapat mengesan 0.1 ng DNA A. terreus dan 10 pikogram (pg) DNA C. krusei serta C. glabrata. Selain daripada 
pengesanan semua kulat secara am, asai tindak balas rantai polimerase multipleks yang dibangunkan dapat mengesan 
kulat berkepentingan klinikal dan membezakan spesies rintang secara pantas dan tepat, justeru boleh berperanan dalam 
penentuan awal ubatan anti kulat yang efektif bagi pesakit.
Kata kunci: Aspergillus; Candida; Fusarium; PCR multipleks; pengesanan
INTRODUCTION
The last two decades has seen a growing number of 
fungal infections coincident with a dramatic increase in 
the population of severely immunocompromised patients 
due to human immunodeficiency virus infections, organ 
transplants, haematological disorders such as leukaemia 
and other malignancies (Oren & Paul 2014). Intensive 
and aggressive medical practices and treatments such 
as surgery, the use of catheters, injections, radiation, 
chemotherapy, antibiotics and steroids are risk factors for 
fungal infections (Galimberti et al. 2012). However, these 
procedures are necessary and therefore, the incidence of 
fungal infections are expected to increase.
 Although Candida and Aspergillus species are major 
contributors to life-threatening infections, occurrence of 
resistant species and the emergence of previously rare 
fungal species is increasing, resulting from antifungal 
prophylaxis in high-risk patients (Preuner & Lion 
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2009; Rishi & Clark 2011). Candida albicans is still 
the predominant species causing infections, however an 
upward trend was observed for non-albicans Candida 
infections caused by C. glabrata, C. parapsilosis and C. 
krusei (Pfaller & Diekema 2007; Rishi & Clark 2011). 
These Candida species show reduced susceptibility 
towards newer echinocandin drugs such as caspofungin, 
while C. glabrata and C. krusei are widely resistant to the 
long-standing, most frequently used azole drug, fluconazole 
(Pfaller & Castanheira 2016). Prolonged caspofungin 
prophylaxis in neutropenic patients has contributed to 
a significant increase of infections caused by C. krusei 
and C. glabrata (Lortholary et al. 2011; Wisplinghoff et 
al. 2014). Aspergillus fumigatus continues to be the most 
frequent causative agent of invasive aspergillosis however, 
non-fumigatus Aspergillus infections increasingly occurred 
(Azab et al. 2015; Bašková & Buchta 2012). In particular, 
A. terreus has been recognised as resistant towards 
amphotericin B, the highly effective but also highly toxic 
broad-spectrum antifungal drug, with a high mortality 
rate for invasive infections (Blum et al. 2013; Steinbach 
& Perfect 2003). Less frequently observed fungal genera 
associated with very high fatality include Fusarium, 
Scedosporium and members of Mucorales, namely 
Rhizopus and Mucor (Bašková & Buchta 2012). In patients 
with haematological malignancies, Fusarium is the second 
or third most common mould causing infections (Tortorano 
et al. 2014)and are reported to have low susceptibility 
towards azole drugs (Alastruey-Izquierdo et al. 2008). 
Fusarium solani is the species responsible for most human 
infections (50%) followed by F. verticillioides (20%) and 
F. moniliforme (Dignani & Anaissie 2004). 
 The standard approaches used for the diagnosis of 
invasive fungal infections include serological detection of 
circulating fungal antigens, culture of body fluids for fungal 
recovery followed by identification and histopathological 
examination of tissue sections for the presence of fungi. 
Although serological assays are widely used, each one 
is designed to detect a single fungal genus and tests for 
Aspergillus and Candida have shown variable sensitivity 
and specificity (Bašková & Buchta 2012; Denning 1998), 
which is similar to culture diagnosis. While histological 
analyses of biopsy tissues is highly sensitive and specific 
(Lenka et al. 2007), the method is frequently associated 
with bleeding complication in patients with severe 
thrombocytopenia (Denning 1998). Poor outcome in 
patients with invasive fungal infections (IFIs) is related to 
delayed institution of an effective antifungal regime and 
prescription of unnecessary toxic antifungal agents (Yeo 
& Wong 2002). 
 In recent years, nucleic acid detection techniques have 
been developed to provide an early diagnosis of mycotic 
infections and the identification of pathogenic fungi. 
Polymerase chain reaction (PCR) based methods including 
nested or semi-nested PCR assays are particularly promising 
because of their simplicity, specificity and sensitivity 
(Cerikçioğlu et al. 2010; Than et al. 2012). Multiplex PCR 
has been used to detect Candida spp. (Mallus et al. 2013; 
Vahidnia et al. 2015) and Aspergillus spp. (Amini et al. 
2015; Logotheti et al. 2009) as has real-time PCR (Emam 
& Abd El-salam 2015; Horváth et al. 2013). Several 
PCR techniques have targeted ribosomal DNA of Candida 
(Cerikçioğlu et al. 2010; Mallus et al. 2013; Than et al. 
2012) and Aspergillus (Walsh et al. 2011). Although these 
PCR methods have been useful for the identification of 
fungal species, they either only identify species within 
a particular genus or detect the fungus at genus level. 
Furthermore, real-time PCR requires the use of costly 
reagents and instrumentation.
 Therefore, in this study multiplex PCR assays were 
developed for simultaneous detection of Candida, 
Aspergillus, Fusarium and the antifungal-resistant species 
A. terreus, C. glabrata and C. krusei through distinct 
amplicon sizes. An optimized multiplex PCR assay with gel 
electrophoresis detection is a very useful, low-cost method 
for the detection of major fungal targets, simultaneously.
MATERIALS AND METHODS
Primers were designed from internal transcribed spacer 
(ITS) regions of fungal ribosomal gene complex (Table 
1). The rDNA sequences of the fungi were retrieved from 
GenBank database and were subjected to the software 
CLUSTALW (http://www.genome.jp/tools/clustalw) for 
multiple sequence alignment. The sequences were analyzed 
with BioEdit Sequence Alignment Editor Version 7.2.3 for 
nonhomologous regions among 101 different fungal strains 
(Table 2). The conserved regions within each targeted 
genus and species were compared for sequence consistency 
against multiple strains of each species. The primer regions 
were tested in silico using the BLAST program (http://blast.
ncbi.nlm.nih.gov) to check for specificity towards the 
target fungi. Genus/species-specific primer sequences were 
analyzed in OligoAnalyzer 3.1 program (https://sg.idtdna.
com/analyzer/Applications/OligoAnalyzer) to analyse its 
reverse complementary sequence, melting temperature, GC 
content and molecular weight. The selected primers were 
synthesized by IDT Singapore. 
 A total of 84 clinical fungal isolates were evaluated in 
this study. These include the filamentous fungi Aspergillus 
fumigatus (n= 4), A. niger (n=9), A. flavus (n=3), A. terreus 
(n=1), Fusarium solani (n=11) and the yeast Candida 
albicans (n= 27), C. tropicalis (n=8), C. parapsilosis 
(n=6), C. krusei (n=3), C. glabrata (n=9), C. kefyr (n= 
1), C. dublinensis (n=1) and Cryptococcus neoformans 
(n=1). Additionally, 6 ATCC (American Type Culture 
Collection) strains of C. albicans ATCC 10231, C. glabrata 
ATCC 66032, C. krusei ATCC 6258, C. parapsilosis ATCC 
20246, A. fumigatus ATCC 204305 and F. solani ATCC 36031 
were evaluated. Clinical fungal isolates were provided 
by the Mycology Unit, UKMMC (Universiti Kebangsaan 
Malaysia Medical Centre) and were identified using 
routinely used methods which include biochemical tests 
for yeasts and microscopic morphology for moulds. In 
addition, DNA from bacterial isolates namely Escherichia 
coli and Staphylococcus aureus was also evaluated for 
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control purpose. The bacterial isolates were obtained from 
the culture collection of the Novel Antibiotic Research 
Laboratory, UKM.
 The fungal isolates were sub-cultured onto Potato-
Dextrose Agar (PDA) or Sabouraud-Dextrose Agar (SDA) 
(Difco Laboratories, West Molesey, UK) media at 25-30ºC; 
2 days for the yeast and 2 weeks for the moulds. To extract 
DNA, two hundred microliters of fungal cell suspension was 
placed on QIAcard FTA Card (Qiagen, Hilden, Germany), 
allowed to dry and microwaved on high power for 30 s. 
Two discs of 3.0 mm diameter of QIAcard FTA was punched 
using Harris Uni-Core™ micro-puncher (Ted Pella, 
California, USA) followed by extraction with Extract-N-
Amp™ Plant PCR kit (Sigma, Missouri, USA). The extracted 
genomic DNA was diluted ten-fold with nuclease free water 
before proceeding to PCR amplification (BIO-RAD T 100™ 
TABLE 1. Genus and species specific primers for fungal targets (patent pending)
Target Primer 
designation
Sequence (5’à3’) Approximate amplicon size (base pair)
Universal detection
All fungi ITS1 TCC GTA GGT GAA CCT GCG G 500 for Candida albicans, C. dubliniensis, 
C. parapsilosis, C. tropicalis, C. kefyr, 480 
for C. krusei & 860 for C. glabrata 
ITS4 TCC TCC GCT TAT TGA TAT GC 550 for Aspergillus fumigatus, A. niger, A. 
flavus, A. terreus & Fusarium solani 
Genus-specific detection
Aspergillus GSAsp1 AAT CAC ACT CAG ACT GCA 200
Candida GSCand1 GTA TYR CTC AAY ACC AAA C 340; 600 for C. glabrata
Fusarium GSFus1 TAC TAC GCW ATG GAA GCT 450
Species-specific detection
Aspergillus terreus SSAter1 CAA GTT GCA AAT AAA TGC 510
Candida glabrata SSCglab1 GCA GAT TAA TAG AGA AGC TTG 700
Candida krusei SSCkrusei2 CTC TGC GCA CGC GCA AGA TG 280
TABLE 2. Strains analysed and experimentally tested for genus specific primer design for Candida, 
Aspergillus, Fusarium and species specific primer for Aspergillus terreus, Candida glabrata, Candida krusei
Genus (No. of strains analysed in silico) (No. of strains experimentally tested)
Candida spp. (Total = 32) 
C. albicans (4) 
C. dubliniensis (1) 
C. tropicalis (2) 
C. parapsilosis (3)
C. krusei (11) 
C. glabrata (10) 
C. guilliermondi (1)








Aspergillus spp. (Total = 31) 
A. fumigatus (8) 
A. terreus (9) 
A. clavatus (3)
A. niger (6) 
A. flavus (4) 
A. nidulans (1)





Fusarium spp. (Total = 12) 
 F. solani (9) 
 F. oxysporum (3)
Fusarium spp. (Total = 12)
F. solani (12)
Species (No. of strains analysed in silico) 
C. glabrata (9) 
C. krusei (9) 
A. terreus (8) 





Thermal Cycler, Germany). 
 The multiplex PCR reaction for fungal genus detection 
contained 2 μL of genomic DNA, 2× GoTaq® Green Master 
Mix that consisted of GoTaq® DNA Polymerase, 400 μM 
dNTP and 3mM MgCl2 (Promega, Madison, WI, USA), 
0.1 μM of primer ITS 4 and 0.4 μM of primer ITS 1, genus 
specific Aspergillus (GSAsp1), Candida (GSCand1), F. 
solani (GSFus1) and species specific C. krusei (SSCkrusei2) 
primers in a total volume of 10 μL. Multiplex PCR reaction 
for resistant species identification contained 2 μL of 
genomic DNA, 2× GoTaq® Green Master Mix and 0.4 μM 
of ITS 1 primer and species specific C. krusei (SSCkrusei2), 
C. glabrata (SSCglab1) and A. terreus (SSAter1) primers 
in a total volume of 10 μL. Optimized PCR amplification 
conditions were: 5 min initial 94ºC step, followed by 34 
cycles at 94ºC for 1.5 min, 51.5ºC for 2 min and 65ºC for 3 
min and a final extension step at 65ºC for 10 min. A patent 
of the designed genus and species specific primers (Table 
1) and multiplex PCR assay procedure submitted to the 
Intellectual Property Corporation of Malaysia (MyIPO) is 
pending (Malayisa Patent Application No. PI 2015001974). 
Amplification products were electrophoresed in agarose 
gels (3.0% w/v) (Vivantis, California, USA) in 0.5 ×TBE 
buffer and stained with ethidium bromide (Nacalai Tesque, 
Kyoto, Japan). 
 The limit of detection of the multiplex PCR assays was 
determined using serial dilutions of fungal DNA extracted 
with Wizard Genomic DNA Purification kit (Promega, 
Madison, WI, USA). 
RESULTS
Each genus and species-specific primer was specific for 
its target as tested in multiplex PCR assays (Figures 1 and 
2) and all the 83 fungal targets were correctly identified 
according to amplicon size. All Aspergillus species strains 
(n=17) were successfully amplified by ITS 1- GSAsp1 
primer pair producing amplicons of approximately 200 
base pair (bp). The Candida genus-specific primer pair 
ITS1-GSCand1 amplified an approximately 340 bp product 
for all Candida spp. Strains (n=43) except for C. glabrata 
strains (n=9) which had an approximate amplicon size of 
600 bp (Figure 3). The Candida genus-specific primer did 
not amplify C. krusei strains. Therefore, C. krusei-specific 
primer pair ITS1-SSCkrusei2 was included in the PCR 
reaction and produced an approximately 310 bp amplicon 
for C. krusei strains (n=3). The F. solani strains (n=11) 
were amplified by Fusarium genus-specific primer pair 
ITS1- GSFus1 yielding approximately 450 bp amplicon. In 
the genus specific assay, the amplification product of the 
universal fungal primers, ITS1 and ITS4 was also detected, 
therefore the larger amplicon served to confirm the 
presence of a fungal target. A Cryptococcus neoformans 
isolate produced an amplicon of approximately 500 bp with 
the universal fungal primers, while the bacterial species 
tested were not detected. In the species differentiation 
assay, species specific primers together with the universal 
fungal primer ITS 1 were used to identify A. terreus, C. 
glabrata and C. krusei. A strain of A. terreus was amplified 
FIGURE 1. Genus-specific multiplex PCR with mixed genomic DNA of F. solani, C. albicans, C. krusei and A. fumigatus (lane 
2) compared with single genomic DNA multiplex PCR as a reference (lanes: 3-6). Lane 2: Universal fungal detection (ITS1 
& ITS4 primers) for (arrows indicate, respectively, from top to bottom) filamentous fungi (~550 bp) and yeast (~500 bp), 
genus specific detection of F. solani (~450 bp), C. albicans (~340 bp), C. krusei (~310 bp) and A. fumigatus (~200 bp). Lane 
3: Universal fungal detection of F. solani (~550 bp) and genus specific amplicon (~450 bp), lane 4: C. krusei (~500 bp & 
~310 bp), lane 5: C. albicans (~500 bp & ~340 bp) and lane 6: A. fumigatus (~550 bp & ~200 bp)
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using the primer pair ITS1-SSAter1 yielding approximately 
510 bp amplicon and 9 strains of C. glabrata were 
amplified by the C. glabrata-specific primer pair ITS1-
SSCglab1 producing amplicons of approximately 700 bp. 
C. krusei-specific primer pair ITS1-SSCkrusei produced the 
same amplicon size as before, of 310 bp. 
 Optimum cycling conditions was achieved with 
annealing temperature set at 51.5ºC and extension 
temperature at 65ºC for 35 cycles. The components of 
the PCR reaction were also optimized with ITS 4 primer 
concentration reduced to 0.1 μM whereas other primers 
were retained at 0.4 μM. Under these optimum conditions 
the limit of detection (LOD) for the genus specific assay 
was 1 ng DNA for A. fumigatus and C. albicans, 0.1 ng 
DNA for F. solani, while the species specific assay detected 
0.1 ng DNA of A. terreus, 10 pg DNA of C. krusei and C. 
glabrata. 
DISCUSSION
In this study, a dual-panel multiplex PCR assay was 
developed and tested for its accuracy and sensitivity in 
detecting Candida, Aspergillus and Fusarium spp. isolates. 
Three primers for individual genus detection and another 
three primers for C. glabrata, C. krusei and A. terreus were 
designed and optimised for multiplex detection of the fungal 
targets. 
 The ITS 1- 5.8S- ITS 4 region was chosen for the design 
of genus and species-specific primers, due to high nucleotide 
variability among genera and species. The ITS region is 
a good molecular target for species level identification 
(Landlinger et al. 2009) and is extensively used as a universal 
DNA barcode in fungal taxonomy studies (Sulaiman et al. 
2014). Furthermore, it is present at approximately 100 
copies per genome (Henry et al. 2000) and is not found in 
FIGURE 2. Species-specific multiplex PCR performed with mixed genomic DNA of C. glabrata, 
A. terreus and C. krusei (lane: 2) compared with single genomic DNA as a reference (lanes: 3-5). 
Lane 2: C. glabrata (~700 bp), A. terreus (~510 bp) and C. krusei (~310 bp). Lane 3: C. glabrata 
(~700 bp), lane 4: A. terreus (~510 bp), lane 5: C. krusei (~310 bp)
FIGURE 3. Genus-specific detection of C. albicans and C. glabrata performed in 
simplex PCR assay (primer ITS1-GSCand1) showing different sizes of amplicon. 
Lane 2-3: C. albicans (~340 bp) and lane 4-5: C. glabrata (~600 bp)
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prokaryotic and human genomes (Than et al. 2012). The 
genus and species specific primers for genera and species 
levels identification were used in two separate assays to 
facilitate the interpretation of results and reduce reaction 
complexity. These two assays have the same PCR cycling 
conditions thus both reactions may be run together. The 
genus specific multiplex PCR reactions were optimized to 
simultaneously amplify two different loci by the genus 
specific primer with ITS 1 and ITS 1 with ITS 4, producing two 
distinctive amplicon sizes. The use of the universal fungal 
primers ITS1 and ITS 4 in this assay enables detection of any 
other fungal pathogen that may cause infections in patients, 
hence is an added advantage of this PCR assay. 
 The Candida genus-specific primer did not detect C. 
krusei strains which are genetically diversified from other 
pathogenic Candida spp. (Berrouane & Hollis 1996) and 
found to be 60 to 70% different in their DNA sequence 
pattern compared to other Candida spp. However, the 
non-amplification of C. krusei strains by Candida-genus 
specific primer and ITS 1 does not impact the outcome of 
this multiplex PCR assay as the C. krusei-specific primer, 
included in the reaction mix, detects C. krusei strains with 
amplicon size similar to Candida genus specific primer. C. 
glabrata strains are distinctive even in the genus-specific 
PCR producing the largest amplicon (approximately 600 bp) 
among targeted regions. 
 No cross reactivity was detected with other clinically 
important fungal, bacterial and human DNA by the BLAST 
program and subsequent experiments carried out with the 
Aspergillus, Candida and Fusarium genus-specific primer 
pairs and Aspergillus terreus, C. glabrata and C. krusei 
species-specific primer pairs. There was no amplification of 
non-target species isolates by these primers, as observed in 
gel electrophoresis, following extensive cross-amplification 
assays. This proves the high specificity of the primers to 
detect the respective genus and species making them suitable 
for use in a multiplex PCR assay. To confirm that the correct 
target was amplified, the PCR amplified product for each 
pair of primers used was sequenced and the results were as 
expected.
 The species specific multiplex PCR assay targeted C. 
krusei, C. glabrata and A. terreus due to their reduced 
susceptibility or resistance to the major prescribed antifungal 
drugs, therefore their detection at the earliest stage will aid 
in appropriate selection of antifungal treatments for patients.
  Current epidemiological trends recognize A. terreus 
as the second or the third most common etiological agent 
of invasive aspergillosis (Neal et al. 2011) especially in 
patients with haematological malignancies (Steinbach & 
Perfect 2003). In vitro and in vivo studies have demonstrated 
that isolates of A. terreus are associated with resistance to 
the antifungal drug amphothericin B, the empirical therapy 
for serious, invasive infections (Bašková & Buchta 2012). 
Furthermore, a recent study found a slight increase in 
invasive fungal infections due to non-albicans Candida 
infections, including Candida glabrata and Candida 
krusei in granulocytopenic and immunocompromised 
patients (Vazquez et al. 2013). C. krusei caused a higher 
mortality rate of 49% among immunocompromised patients 
as compared to 28% mortality by C. albicans infections 
(Richardson & Lass-Flörl 2008). C. krusei and C. glabrata 
were highly resistant to fluconazole (Chang et al. 2001) 
and less susceptible to itraconazole and amphotericin B 
(Abbas et al. 2000). The incidence of non-albicans Candida 
infections has been attributed to the widespread use of 
fluconazole as a prophylaxis antifungal (Cuenca-Estrella 
et al. 2008). 
 In order for PCR to be a sensitive diagnostic tool for 
invasive disease, a limit of detection (LOD) of <10 CFU/
mL of blood should be achieved (Avni et al. 2011). The 
genus-specific multiplex PCR assay achieved an LOD of 
0.1-1 ng DNA while the species-specific assay detected 10 
pg-1 ng DNA. The fungal genome has an average size of 
approximately 0.038 pg or approximately 1.9 pg DNA in 50 
cells (Gregory et al. 2007). Therefore, the sensitivity of the 
PCR assays should be increased, by increasing the number 
of PCR cycles to achieve the desired sensitivity for clinical 
application.
CONCLUSION
The multiplex PCR assays described here are able to 
differentiate three major clinically important fungal 
genera, namely Candida, Aspergillus and Fusarium and 
the resistant species A. terreus, C. glabrata and C. krusei. 
The deployment of a rapid, low cost yet reliable method for 
early diagnosis of invasive fungal infections is paramount 
to improving clinical management of the disease especially 
in hospitals with limited resources. 
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SUPPLEMENTARY FILE
SUPPLEMENTARY 1. Gel electrophoresis of PCR product using 
DNA sample from Candida spp. isolates, with universal primers 
ITS 1 and ITS 4. Lane 1: 100 bp DNA ladder. Lane 2: Candida 
albicans MM 0692. Lane 3: C. krusei ATCC 6258. Lane 4: C. 
dubliensis MM 2524. Lane 5: Candida albicans MM 566. Lane 
6: C. glabrata MM 0691. Lane 7: C. glabrata ATCC 66032. Lane 
8: C. parapsilosis MM 0884. Lane 9: C. parapsilosis MM 6950. 
Lane 10: C. parapsilosis ATCC 20246. Lane 11: Cryptococcus 
neoformans D 13080. Lane 12: C. albicans ATCC 10231
SUPPLEMENTARY 2. Gel electrophoresis of PCR product using 
set of universal primers ITS 1 & ITS 4 (Lane 2) and set of 
Candida genus-specific primer, GSCand1 & ITS 1 with DNA 
isolates of different species (Lane 3 to Lane 10). Lane 1: 100 
bp DNA ladder. Lane 2: positive control, C. albicans MM 
1076. Lane 3: positive control, C. parapsilosis MM 1113. Lane 
4: A. fumigatus MM 956. Lane5: A. niger MM 2735. Lane 6: 
A. flavus MM 1938. Lane 7: F. solani MM 0020. Lane 8: S. 
aureus. Lane 9: Syctalidium sp. Lane 10: E. coli
SUPPLEMENTARY 3. Gel electrophoresis of PCR product for 
sensitivity detection test using DNA isolate of C. albicans in 
multiplex PCR assay set 1. Lane 1: 100 bp DNA ladder. Lane 2: 
DNA concentration of 0.5 ng/μL. Lane 3: DNA concentration of 
0.05 ng/μL. Lane 4: DNA concentration of 5.0 pg/μL. Lane 5: 
DNA concentration of 0.5 pg/μL. Lane 6: negative control
SUPPLEMENTARY 4. Gel electrophoresis of PCR product for 
sensitivity detection test using DNA isolate of C. krusei in 
multiplex PCR assay set 1. Lane 1: 100 bp DNA ladder. Lane 2: 
DNA concentration of 0.5 ng/μL. Lane 3: DNA concentration of 
0.05 ng/μL. Lane 4: DNA concentration of 5.0 pg/μL. Lane 5: 
DNA concentration of 0.5 pg/μL. Lane 6: negative control
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SUPPLEMENTARY 5. Gel electrophoresis of PCR product for 
sensitivity detection test using DNA isolate of A. fumigatus in 
multiplex PCR assay set 1. Lane 1: 100 bp DNA ladder. Lane 2: 
DNA concentration of 0.5 ng/μL. Lane 3: DNA concentration of 
0.05 ng/μL. Lane 4: DNA concentration of 5.0 pg/μL. Lane 5: 
DNA concentration of 0.5 pg/μL. Lane 6: negative control
SUPPLEMENTARY 6. Gel electrophoresis of PCR product for 
sensitivity detection test using DNA isolate of A. terreus in 
multiplex PCR assay set 2. Lane 1: 100 bp DNA ladder. Lane 2: 
DNA concentration of 0.5 ng/μL. Lane 3: DNA concentration of 
0.05 ng/μL. Lane 4: DNA concentration of 5.0 pg/μL. Lane 5: 
DNA concentration of 0.5 pg/μL. Lane 6: negative control
SUPPLEMENTARY 7. Gel electrophoresis of PCR product for sensitivity detection 
test using DNA isolate of F. solani in multiplex PCR assay set 1. Lane 1: 
100 bp DNA ladder. Lane 2: DNA concentration of 0.5 ng/μL. Lane 3: DNA 
concentration of 0.05 ng/μL. Lane 4: DNA concentration of 5.0 pg/μL. 
Lane 5: DNA concentration of 0.5 pg/μL. Lane 6: negative control
